financetom
Business
financetom
/
Business
/
Viavi Solutions' Fiscal Q3 Buoyed By Recovery in Network Enablement Segment, Morgan Stanley Says
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Viavi Solutions' Fiscal Q3 Buoyed By Recovery in Network Enablement Segment, Morgan Stanley Says
May 26, 2025 12:33 AM

01:50 PM EDT, 05/02/2025 (MT Newswires) -- Viavi Solutions' ( VIAV ) fiscal Q3 earnings came in-line with expectations buoyed by some recovery in the network enablement segment but weaker than other business operating in the space, Morgan Stanley said in a note emailed Friday.

"While no cancellations, downsizing, or pullforward of deals seen to-date, tariffs incorporated in [purchase orders] may lead to potential deal slippage given time required to get signatures," Morgan Stanley said.

Viavi Solutions ( VIAV ) reported fiscal Q3 non-GAAP earnings of $0.15 per diluted share, compared with analysts' estimate of $0.12.

Net revenue was $284.8 million, slightly above the estimate of $282.1 million.

According to Morgan Stanley, further upside to the business was now dependent on "meaningful EPS revisions" which appeared limited given the tariff overhang.

The firm added that it remained "cautious" as service provider budgets did not have the same ability to absorb tariffs when compared to other customers.

Viavi Solutions ( VIAV ) is targeting fiscal Q4 non-GAAP EPS of $0.10 to $0.13 on net revenue of $278 million to $290 million. Analysts project EPS of $0.12 on revenue of $285.2 million.

Morgan Stanley reiterated its underweight rating on the stock and raised its price target to $8.60 from $8 previously.

Price: 9.02, Change: -1.63, Percent Change: -15.28

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Axsome Therapeutics Says FDA Accepts Potential Migraine Treatment Resubmission
Axsome Therapeutics Says FDA Accepts Potential Migraine Treatment Resubmission
Sep 6, 2024
10:54 AM EDT, 09/04/2024 (MT Newswires) -- Axsome Therapeutics ( AXSM ) said Wednesday the US Food and Drug Administration has accepted the resubmission of its New Drug Application for AXS-07 to potentially treat migraine. The FDA has classified it as a Class 2 resubmission, with a Prescription Drug User Fee Act target action date of Jan. 31, 2025, the...
Amgen aims to treat liver, kidney diseases with obesity drug
Amgen aims to treat liver, kidney diseases with obesity drug
Sep 6, 2024
By Puyaan Singh Sept 4 (Reuters) - Amgen ( AMGN ) will test its obesity drug candidate in patients at risk of weight-related conditions such as heart, liver and kidney diseases in its late-stage trial, the company's CEO Robert Bradway said on Wednesday. Speaking at a Morgan Stanley healthcare conference, Bradway described MariTide as a next-generation obesity drug due to...
Knightscope Wins New Emergency Communication Contracts
Knightscope Wins New Emergency Communication Contracts
Sep 6, 2024
10:50 AM EDT, 09/04/2024 (MT Newswires) -- Knightscope ( KSCP ) said Wednesday it has obtained three new contracts for its emergency communication devices, or ECDs. The company said its authorized partner Colonial Electric sold four K1 Blue Light Towers to a client in New Jersey. Universities in California and Texas also decided to expand existing contracts to include long-term...
Reports of dollar's demise are greatly exaggerated, JPMorgan says
Reports of dollar's demise are greatly exaggerated, JPMorgan says
Sep 6, 2024
LONDON (Reuters) - Suggestions that the dollar's dominance of the global financial system is ending are wide of the mark, JPMorgan said on Wednesday, despite some dramatic signs of change in commodity markets and certain trading blocs. China's rise and the use of economic sanctions on the likes of Russia mean there is a trend of diversification away from the...
Copyright 2023-2026 - www.financetom.com All Rights Reserved